Eloxx Pharmaceuticals, Inc. (ELOX) Income Statement
ELOX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsELOX revenue and net income
ELOX profit margins
ELOX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ELOX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $75,000 |
| Cost of revenue | — | $0 | — | $695,000 | $960,000 | $571,000 | $559,000 | $216,000 | $39,000 | $93,394 |
| Gross profit | — | $6.4M | — | −$695,000 | −$960,000 | −$571,000 | −$559,000 | −$216,000 | −$39,000 | −$18,394 |
| Research & development | $3.1M | $3.6M | $8.6M | $23.7M | $22.9M | $14.6M | $25.8M | $20.5M | $16.4M | $2.1M |
| Sales, general & admin | $3.4M | $5.2M | $8.7M | $10.7M | — | — | — | — | — | — |
| Total operating expenses | $6.4M | $8.8M | $17.3M | $33.7M | $41.4M | $28.9M | $50.0M | $46.8M | $20.4M | $3.7M |
| Operating income | −$6.4M | −$2.5M | −$17.3M | −$34.4M | −$42.3M | −$29.4M | −$50.6M | −$47.0M | −$20.4M | −$3.7M |
| Interest income | $33,000 | $27,000 | $252,000 | $274,000 | — | — | — | — | — | — |
| Interest expense | $1.0M | $1.1M | $1.2M | $1.9M | $1.3M | $1.4M | $1.6M | $7,000 | $668,000 | — |
| Income before taxes | −$6.0M | −$3.1M | −$17.1M | −$36.1M | −$66.7M | −$34.6M | −$50.9M | −$47.1M | −$21.2M | −$8.9M |
| Income taxes | — | — | — | −$77,000 | — | — | — | $122,000 | — | −$680,000 |
| Net income | −$6.0M | −$3.1M | −$17.1M | −$36.1M | −$66.7M | −$34.6M | −$50.9M | −$47.2M | −$21.2M | −$8.3M |
| EBITDA | −$4.9M | −$1.8M | −$15.1M | −$33.5M | −$64.5M | −$28.9M | −$50.0M | −$46.8M | −$20.4M | −$3.6M |
| EPS (diluted) | −$17.28 | — | −$68.27 | −$183.16 | −$339.92 | −$378.72 | −$559.67 | −$578.96 | — | — |
| Gross margin | — | 100.0% | — | — | — | — | — | — | — | −24.5% |
| Operating margin | — | −38.8% | — | — | — | — | — | — | — | −4,952.0% |
| Net margin | — | −49.4% | — | — | — | — | — | — | — | −11,023.9% |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | $188,000 | $185,000 | $186,000 | $178,000 | $189,000 | $129,000 | $198,000 | $202,000 |
| Gross profit | — | — | — | — | −$188,000 | −$185,000 | −$186,000 | −$178,000 | −$189,000 | −$129,000 | −$198,000 | −$202,000 |
| Research & development | $2.8M | $1.7M | $898,000 | $510,000 | $1.2M | $2.3M | $3.5M | $3.3M | $4.9M | $7.7M | $7.9M | $7.9M |
| Sales, general & admin | $1.6M | $2.1M | $684,000 | $712,000 | — | — | — | — | — | — | — | — |
| Total operating expenses | $4.5M | $3.8M | $1.6M | $1.2M | $3.4M | $4.0M | $5.3M | $5.8M | $7.0M | $10.2M | $10.8M | $11.4M |
| Operating income | −$4.5M | −$3.8M | −$1.6M | −$1.2M | −$3.6M | −$4.1M | −$5.5M | −$6.0M | −$7.1M | −$10.3M | −$11.0M | −$11.6M |
| Interest income | $41,000 | $23,000 | $3,000 | $5,000 | — | — | — | — | — | — | — | — |
| Interest expense | $8,000 | $29,000 | $308,000 | $483,000 | $235,000 | $230,000 | $485,000 | $581,000 | $489,000 | $475,000 | $404,000 | $456,000 |
| Income before taxes | −$4.5M | −$3.8M | −$1.9M | −$1.7M | −$3.6M | −$4.3M | −$6.2M | −$6.4M | −$7.5M | −$10.6M | −$11.6M | −$12.1M |
| Income taxes | — | — | — | — | — | — | — | −$77,000 | — | — | — | — |
| Net income | −$4.5M | −$3.8M | −$1.9M | −$1.7M | −$3.6M | −$4.3M | −$6.2M | −$6.3M | −$7.5M | −$10.6M | −$11.6M | −$12.1M |
| EBITDA | −$4.5M | −$3.7M | −$1.6M | −$1.2M | −$3.2M | −$3.9M | −$5.6M | −$5.6M | −$6.8M | −$10.0M | −$11.0M | −$11.4M |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ELOX's financial statements (latest annual report filed March 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ELOX financial results
Eloxx Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $6.0 million. Diluted earnings per share came to −$17.28.
See the ELOX stock overview for the latest quote and news, or the ELOX chart for price history and technical indicators.
ELOX income statement FAQ
Does Eloxx Pharmaceuticals have revenue?
Eloxx Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Eloxx Pharmaceuticals profitable?
No. Eloxx Pharmaceuticals reported a net loss of $6.0 million in fiscal 2025.
How much does Eloxx Pharmaceuticals spend on research and development?
Eloxx Pharmaceuticals spent $3.1 million on research and development in fiscal 2025.
What are Eloxx Pharmaceuticals's earnings per share?
Eloxx Pharmaceuticals earned $-17.28 per diluted share in fiscal 2025.
When will Eloxx Pharmaceuticals report its next earnings?
Eloxx Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 10, 2026.
When does Eloxx Pharmaceuticals's fiscal year end?
Eloxx Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 17, 2026.